Safety, Efficacy, and Immunogenicity of a Salmonella Paratyphi A Vaccine.

Naina McCann^1,2, Margarete Paganotti Vicentine^1,2, Narges Ebrahimi^1,2, Melanie Greenland^1,2, Brian Angus^1,2, Andrea M Collins^3,4, Thomas Darton⁵, Katherine Emary^1,2, Saul N Faust^6,7, Amy Flaxman^1,2, Noshi Maria^1,2, Christopher A Green⁸, Claudia Juarez Molina^1,2, Ravindra Paidisetti⁹, Rajeka Lazarus^10,11, Grace C Macaulay^1,2, Florence McLean^1,2, V Krishna Mohan⁹, M Gangadhara Naidu⁹, Maheshi N Ramasamy^1,2,12, D Yogeswara Rao⁹, Nisha Singh^1,2, Sophie Vernon^1,2, Young Chan Kim^1,2, Myron M Levine¹³, Xinxue Liu^1,2, Andrew J Pollard^1,2,

¹Oxford Vaccine Group, Department of Paediatrics, Centre for Clinical Vaccinology and Tropical Medicine, Churchill Hospital, Oxford, United Kingdom.

²National Institute for Health and Care Research (NIHR) Oxford Biomedical Research Centre, Oxford, United Kingdom.

³Liverpool University Hospitals Foundation Trust, Liverpool, United Kingdom.

⁴Liverpool School of Tropical Medicine, Liverpool, United Kingdom.

⁵Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield, United Kingdom.

⁶NIHR Southampton Clinical Research Facility and Biomedical Research Centre, University Hospital Southampton NHS Foundation Trust, Southampton, United Kingdom.

⁷Faculty of Medicine and Institute for Life Sciences, University of Southampton, Southampton, United Kingdom.

⁸NIHR-Wellcome Clinical Research Facility, University Hospitals Birmingham NHS Foundation Trust, Birmingham, United Kingdom.

⁹Bharat Biotech International, Hyderabad, India.

¹⁰Bristol Medical School, University of Bristol, Bristol, United Kingdom.

¹¹U.K. Health Security Agency Southwest Regional Laboratory and Vaccine Development and Evaluation Centre, Bristol, United Kingdom.

¹²Oxford University Hospitals NHS Foundation Trust, Oxford, United Kingdom.

¹³Center for Vaccine Development and Global Health, University of Maryland School of Medicine, Baltimore.

PubMed DOI

Abstract

BACKGROUND: Salmonella enterica serovar Paratyphi A (also known as S. Paratyphi A) is responsible for more than 2 million cases of enteric fever annually. There are no licensed vaccines against S. Paratyphi A. METHODS: In a double-blind, randomized, placebo-controlled trial, we evaluated an orally administered live, attenuated S. Paratyphi A vaccine (CVD 1902) using a controlled human infection m…

Create a free account to keep reading

Free members get 10 full research views every month across publications, clinical trials, FDA clearances, adverse events, and NIH grants. No credit card required.

Create Free Account Sign In

Want unlimited research access? See Pro plans

Data Accuracy Notice: Research intelligence on Health AI Central is aggregated from public sources (PubMed, ClinicalTrials.gov, FDA, NIH, CMS, and others) and refreshed nightly. Classifications and derived metrics are produced by automated methods described in our Methodology. We recommend verifying critical data points against the primary sources before making decisions.